Ina Geerts

Ms. Ina Geerts

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2025 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
IGIna Geerts
Ina Geerts
Katrien BenhalimaKatrien Benhalima
Katrien Benhalima

27 August 2026 in BMC Medicine
Verified
Journal Article
Open access
PDF file
IGIna Geerts
Ina Geerts
CYCatherine Yu
Catherine Yu
NENina Embo
Nina Embo
Katrien BenhalimaKatrien Benhalima
Katrien Benhalima
The incidence of gestational diabetes mellitus (GDM) is rising along with rates of obesity and type 2 diabetes. GDM is associated with an increased risk of

29 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IGIna Geerts
Ina Geerts
CYCatherine Yu
Catherine Yu
NBNiels Bochanen
Niels Bochanen
EHEllen Heyns
Ellen Heyns
IPInge Van Pottelbergh
Inge Van Pottelbergh
Katrien BenhalimaKatrien Benhalima
Katrien Benhalima
Background/Objectives: Gestational diabetes mellitus (GDM) is associated with increased short- and long-term risks for both mother and child. Screening and treatment between 24 and 30 weeks’ gestation reduces adverse pregnancy outcomes, while emerging evidence suggests that earlier diagnosis and treatment (<20 weeks’) in high-risk populations may further improve neonatal outcomes. Currently, self-monitoring of blood glucose (SMBG) remains the standard of care for management but provides only intermittent glycemic data and limited insight into overall glucose patterns. Real-time continuous glucose monitoring (rt-CGM) has transformed management in pregnancies complicated by type 1 diabetes but has shown conflicting results in GDM; it is thus unclear whether similar benefits may extend to women with GDM, including women with early GDM. Methods: The Continuous Glucose Monitoring for Women With Gestational Diabetes (CORDELIA) study is an ongoing, large, open-label, multicenter randomized controlled trial conducted across 14 centers in Belgium and two centers in Australia. Women diagnosed with GDM are randomized in a 1:1 ratio to either rt-CGM (intervention group) or standard care with SMBG (control group). Both women with early GDM diagnosed before 20 weeks’ gestation and those diagnosed between 24.0 and 29.6 weeks’ gestation are included. Participants attend the following visits: baseline visit at GDM diagnosis, an additional visit at 20.0–23.9 weeks’ (if early GDM), 31.0–33.6 weeks’ and 36.0–38.6 weeks’, and a postpartum oral glucose tolerance test (OGTT) assessment (6.0–23.6 weeks after delivery). At each visit, clinical assessment, HbA1c, and (blinded) CGM are evaluated, alongside validated patient-reported outcome questionnaires. The primary objective is to compare the incidence of a composite of adverse pregnancy outcomes between the rt-CGM and SMBG groups. The primary outcome is a composite of adverse pregnancy outcomes including preterm delivery 24 h, neonatal respiratory distress, stillbirth or neonatal death, phototherapy, birth trauma, and shoulder dystocia. Secondary outcomes include maternal glycemia, insulin use, pregnancy and neonatal outcomes, glycemic variability, patient-reported outcomes, and prespecified secondary analyses according to timing of GDM diagnosis and maternal BMI. Trial Registration: ClinicalTrials.gov: NCT06310356. First posted: 15 March 2024.

12 August 2026 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
IGIna Geerts
Ina Geerts
KBKaat Beunen
Kaat Beunen
LBLiese Berger
Liese Berger
NWNancy Van Wilder
Nancy Van Wilder
DBDominique Ballaux
Dominique Ballaux
Katrien BenhalimaKatrien Benhalima
Katrien Benhalima
Objective: To examine the associations between continuous glucose monitoring (CGM) metrics, including glucose management indicator (GMI) and overnight glucose levels, and pregnancy outcomes in women with type 1 diabetes. Research Design and Methods: Secondary exploratory analysis of the CRISTAL trial including 95 pregnant women with type 1 diabetes using CGM. Associations were assessed using logistic regression and Spearman correlations, presented as odds ratios (95% confidence intervals [CIs]) adjusted for baseline HbA1c. GMI validity was assessed using scatter and Bland–Altman plots. Results: Each 5% increase in overall pregnancy-specific time-in-range (TIRp) decreased the odds of gestational hypertension (odds ratio [OR] 0.63, 95% CI 0.41–0.97), birthweight >4.5 kg (OR 0.56, 95% CI 0.32–0.96), and neonatal hypoglycemia requiring hospital care (OR 0.09, 95% CI 0.01–0.57). Each 5% increase in overnight TIRp decreased the odds of gestational hypertension (OR 0.71, 95% CI 0.52–0.98) and neonatal hypoglycemia requiring hospital care (OR 0.15, 95% CI 0.03–0.79). Each 5% increase in overall time-above-range (TARp) increased the odds of birthweight >4.5 kg (OR 1.76, 95% CI 1.05–2.96), respiratory distress (OR 1.55, 95% CI 1.02–2.37), and neonatal hypoglycemia requiring hospital care (OR 5.10, 95% CI 1.14–22.78). Each 5% increase in TARp overnight increased the odds of hospital care for neonatal hypoglycemia (OR 2.55, 95% CI 1.15–5.66). Each 0.28 mmol/L increase in mean glucose and 0.5% increase in GMI were associated with increased respiratory distress (OR 1.54, 95% CI 1.07–2.23 and OR 6.15, 95% CI 1.33–28.40). Every 0.28 mmol/L increase in glycemic variability (SD) was associated with gestational hypertension (OR 1.69, 95% CI 1.02–2.80) and birthweight >4.5 kg (OR 2.31, 95% CI 1.20–4.43). Several combinations of CGM metrics (TIRp[-night], TARp[-night], SD, mean glucose) improved discriminative performance for pregnancy outcomes. GMI and HbA1c values were discordant. Conclusions: Specific combinations of CGM metrics, including overnight TIRp/TARp, may be informative for predicting pregnancy outcomes. GMI and HbA1c should not be considered interchangeable for glycemic control during pregnancy.